This trial is performed to evaluate the safety and clinical efficacy of subcutaneous specific immunotherapy in patients suffering from seasonal allergic rhinitis/rhinoconjunctivitis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
150
subcutaneous injections
subcutaneous injections
Unnamed facility
Hamburg, Germany
Symptom and medication score
Time frame: 1 year
Safety of the treatment
Time frame: 1 year
Documentation of adverse events
Time frame: 1 year
Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)
Time frame: 1 year
Clinical global improvement
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.